CVR 26290724Limited partnership (K/S)Anden finansiel formidling i.a.n. (649990)HellerupFounded 28 Sep 2001
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about NORDIC BIOTECH K/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
0
CVR, 2011
Result
+101.5M
DKK, annual report 2024
Equity
127M
DKK, annual report 2024
NORDIC BIOTECH GENERAL PARTNER ApSCVR 26270367, until 22 Dec 2025
BVF/Nexgen Investments, L.P.25% to under 33.3% of capital and votes, until 22 Dec 2025
European Investment Fund25% to under 33.3% of capital and votes, until 22 Dec 2025
and 4 moreNo current partner is registered.
Liable for the company's debts without limit (fuldt ansvarlige deltagere).
CVR 2627036728 Sep 2001 to 22 Dec 2025
No current owner is registered.
CVR 1629467510% to under 15% of capital and votesnotified 31 Mar 202331 Jul 2002 to 31 Mar 2023
CVR 2185554510% to under 15% of capital and votes13 Apr 2015 to 22 Dec 2025
CVR 4347820610% to under 15% of capital and votes1 Apr 2023 to 22 Dec 2025
25% to under 33.3% of capital and votes31 Jul 2002 to 22 Dec 2025
25% to under 33.3% of capital and votes31 Jul 2002 to 22 Dec 2025
5% to under 10% of capital and votes31 Jul 2002 to 22 Dec 2025
10% to under 15% of capital and votes26 Mar 2015 to 22 Dec 2025
NORDIC BIOTECH K/S holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 2886588020% to under 25% of capital and votes14 Oct 2014 to 26 Nov 2025
CVR 2717496533.3% to under 50% of capital and votes11 Jul 2016 to 23 Apr 2020
CVR 3736403733.3% to under 50% of capital and votes14 Mar 2017 to 4 Oct 2017
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
2011, annual: 0 employees, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2002 | 2008 | Q4 2009 | Q2 2010 | Q3 2010 | 2011 |
|---|---|---|---|---|---|---|
| Employees | 1 | 1 | No count | No count | No count | 0 |
| FTE | 0 | 0 | 0 | 0 | 0 | 1 |
| Series | Annual | Annual | Quarterly | Quarterly | Quarterly | Annual |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest 2011, published 18 Jul 2013.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2024, DKK: Operating profit not reported, Result for the year 101.5M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2024, DKK: Total assets 127.1M, Equity 127M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Operating profit | -1,354 | -6,381 | -44,568 | Not reported | Not reported |
| Result for the year | -1,360 | -6,387 | -44,572 | +1,254 | +101,458 |
| Equity | 85,109 | 78,722 | 34,150 | 32,232 | 127,032 |
| Total assets | 85,170 | 78,784 | 34,208 | 32,326 | 127,129 |
| Employees (average) | 0 | 0 | 0 | Not reported | Not reported |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for NORDIC BIOTECH K/S:
Have Pro? Sign in.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
15 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Virksomheden er slettet af registeret, jf. lov om visse erhvervsdrivende virksomheder § 21
Direktion:
Fratrådte:
CVR-NR. 26270367 NORDIC BIOTECH GENERAL PARTNER ApS, den 22.12.2025.
Revision:
Fratrådte:
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 22.12.2025.
Ny adresse: c/o NB Capital ApS, Strandvejen 125, 2900 Hellerup
Revision:
Fratrådte:
EY Godkendt Revisionspartnerselskab, den 12.06.2023.
Tiltrådte:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Weidekampsgade 6, 2300 København S, den 12.06.2023.
Direktion:
Tiltrådte:
CVR-NR. 26270367 NORDIC BIOTECH GENERAL PARTNER ApS, c/o NB Capital ApS, Østergade 24A, 1. tv, 1100 København K, den 28.09.2001.
CVR-nummer:
26290724.
NAVN:
NORDIC BIOTECH K/S.
Adresse: c/o NB Capital ApS, Østergade 24A, 1. tv., 1100 København K.
Kommune: København.
Retsform: Kommanditselskab.
Revision:
Fratrådte:
null, den 10.10.2014.
Tiltrådte:
CVR-NR. 30700228 ERNST & YOUNG Godkendt Revisionspartnerselskab, Osvald Helmuths Vej 4, 2000 Frederiksberg, den 10.10.2014.
Retsform:
Kommanditselskab.
Vedtægter ændret:
27.05.2014.
Retsform:
Kommanditselskab.
Ny adresse:
c/o NB Capital ApS, Østergade 24A, 1. tv., 1100 København K.
Retsform:
Kommanditselskab.
Investerings Komite:
Udtrådt:
Claus Tycho Bræstrup, den 17.06.2003, Maja Kirstine Elsøe Engmark, den 17.06.2003, Lars Grønborg Eskesen, den 17.06.2003, Matthew Daniel Perry, den 17.06.2003.
Retsform:
Kommanditselskab.
Vedtægter ændret:
20.06.2002.
Bestyrelse:
Udtrådt af bestyrelsen:
Lars Grønborg Eskesen, den 20.06.2002, den 20.06.2002, Claus Tycho Bræstrup, den 20.06.2002, den 20.06.2002, Maja Kirstine Elsøe Engmark, den 20.06.2002, den 20.06.2002, Matthew Daniel Perry, den 20.06.2002, den 20.06.2002.
Investerings Komite:
Indtrådt: Koncerndirektør Claus Tycho Bræstrup, den 20.06.2002, Maja Kirstine Elsøe Engmark, den 20.06.2002, Direktør Lars Grønborg Eskesen, den 20.06.2002, Matthew Daniel Perry, den 20.06.2002.
Selskabet tegnes af komplementaren.
Retsform:
Kommanditselskab.
Vedtægter ændret:
31.07.2002.
Retsform:
Kommanditselskab.
Ny adresse:
Østergade 5, 3., 1100 København K.
Retsform:
Kommanditselskab.
Ny adresse:
Østergade 5, 3., postboks 2034, 1100 København K.
Retsform:
Kommanditselskab.
Første regnskabsår:
28.09.2001 - 31.12.2002.
Retsform:
Kommanditselskab.
Seneste vedtægtsdato:
28.09.2001.
Komplementar: CVR-NR. 26270367 NORDIC BIOTECH GENERAL PARTNER ApS, Ved Stranden 18, postboks 2034, 1012 København K, den 28.09.2001.
Bestyrelse:
Direktør Lars Grønborg Eskesen (formand), den 28.09.2001, Koncerndirektør Claus Tycho Bræstrup, den 28.09.2001, Maja Kirstine Elsøe Engmark, den 28.09.2001, Matthew Daniel Perry, den 28.09.2001.
Virksomheden tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller af komplementaren.
Revision:
CVR-NR. 73317428 ERNST & YOUNG STATSAUTORISERET REVISIONSAKTIESELSKAB, Tagensvej 86, 2200 København N, den 28.09.2001.
Første regnskabsår:
28.09.2001 - 31.12.2001.
Regnskabsår:
01.01 - 31.12.
P-number 1008737955Ved Stranden 18, 1012 København K
P-number 1008776608Strandvejen 125, 2900 Hellerup